OVERVIEW

Annual Meeting - Prostate Pathology Long Course is organized by United States and Canadian Academy of Pathology (USCAP) and will be held from Apr 20, 2018 - Mar 08, 2020.

Target Audience:
Practicing academic and community pathologists, and pathologists-in-training

Continuing Medical Education and Continuing Certification:
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Continuous Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 6.25 SAM credit hours.

Course Description:
Accurate diagnosis, Gleason grading and staging of prostate cancer, and prudent use of ancillary tests are critical for management of prostate cancer patients. However, error in diagnosing, grading and reporting prostate cancer has remained a significant problem in clinical practice, with diagnostic errors that potentially impact clinical management in 1-15% of prostate biopsies.

Gleason grading system has undergone significant modification and a new grading system has been proposed, yet the adoption of these changes in clinical practice is slow. New entities of important clinical significance, such as intraductal carcinoma, have been described. There have been tremendous advances in the understanding of molecular and genetic mechanisms in prostate carcinogenesis and progression which has led to development of multigene genetic and genomic tests. However, there has been a lack of understanding of the new entities and molecular diagnostic tests among practicing pathologists.

Learning Objectives:
Upon completion of this educational activity, learners will be able to:
• Review histological criteria for diagnosing prostate cancer and use of immunohistochemistry markers.
• Review benign mimickers of prostate cancer and cancer that mimics benign prostate lesions.
• Update on recent modifications of Gleason system and the novel grading system (grade grouping).
• Identify the clinical relevant pathological parameters that should be included in the surgical pathology report.
• Learn the new advances in molecular mechanisms in prostate carcinogenesis/progression and clinically relevant genetic tests.

Additional details will be posted as soon as they are available.